Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR T Cells for Malignant Tumors
NCT03302403Phase 1Unknown
- Start
- Dec 2017
- Primary completion
- Dec 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ningetinib, satricabtagene autoleucel, CT011 and CAR-CD19 T cell (Kang YU) in B-cell acute lymphoblastic leukemia (B-ALL), B cell lymphoma, multiple myeloma (MM) and 3 more. Primary endpoint: Number of participants with CAR T-related adverse events at 24 weeks. Status: unknown.
02
Drugs
ningetinibsatricabtagene autoleucelCT011CAR-CD19 T cell (Kang YU)
03
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)B cell lymphomamultiple myeloma (MM)hepatocellular carcinoma (HCC)pancreatic carcinoma
Beyond the preview
Go deeper on NCT03302403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03302403.